Although propranolol has been accepted as a first-line drug for infantile haemangioma (IH), no study has systematically characterized changes in heart rates during long-term propranolol treatment.

Objectives

To evaluate the influence of a divided dose of propranolol on heart rates in patients with IH.

Methods

A prospective study was conducted from January 2009 to December 2013. All patients with IH were administered propranolol at 0·67 mg kg⁻¹ per day as a single dose on days 1 and 2, gradually increased to the full dose (2 mg kg⁻¹ per day) on day 5, which was given in three divided doses. Heart rates were recorded before treatment and were closely monitored during treatment. Heart rates in controls were monitored once a week.

Results

All heart rates monitored during treatment were found to be within the normal range. Fluctuations in heart rates were observed after every dose from the first day to the first dose of the sixth day; however, from the second dose of the sixth day onwards, no significant differences in heart rates were observed after each dose on successive days. During the second week of drug therapy, no significant differences in heart rates were observed at 1 h after the first dose (P = 1·00). Also, no significant differences (P = 0·73) in heart rates were observed between patients and controls at 1 h after the first dose on Mondays from week 1 to 16 of treatment.

Conclusions

A three-times-daily dosing regimen of propranolol had no significant sustained effects on heart rates in subjects with IH.

References

1Garin EH, Araya CE. Treatment of systemic hypertension in children and adolescents. Curr Opin Pediatr 2009; 21: 600–4.
10.1097/MOP.0b013e32832ff3a7
PubMed Web of Science® Google Scholar
2 Haemangioma Investigator Group, Haggstrom AN, Drolet BA et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007; 150: 291–4.
10.1016/j.jpeds.2006.12.003
PubMed Web of Science® Google Scholar
3Margileth AM, Museles M. Cutaneous hemangiomas in children. Diagnosis and conservative management. JAMA 1965; 7: 523–6.
Google Scholar
4Haggstrom AN, Drolet BA, Baselga E et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics 2006; 118: 882–7.
10.1542/peds.2006-0413
PubMed Web of Science® Google Scholar
5Frieden IJ, Haggstrom AN, Drolet BA et al. Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7–9, 2005, Bethesda, Maryland, U.S.A. Pediatr Dermatol 2005; 22: 383–406.
10.1111/j.1525-1470.2005.00102.x
PubMed Google Scholar
6Kim HJ, Colombo M, Frieden IJ. Ulcerated hemangiomas: clinical characteristics and response to therapy. J Am Acad Dermatol 2001; 44: 962–72.
10.1067/mjd.2001.112382
CAS PubMed Web of Science® Google Scholar
7Orlow SJ, Isakoff MS, Blei F. Increased risk of symptomatic hemangiomas of the airway in association with cutaneous hemangiomas in a ‘beard’ distribution. J Pediatr 1997; 131: 643–6.
10.1016/S0022-3476(97)70079-9
CAS PubMed Web of Science® Google Scholar
8Itani MH, Fakih H. Response of facial haemangioma to oral propranolol. BMJ Case Rep 2009; 2009: 1476.
10.1136/bcr.01.2009.1476
Google Scholar
9Léauté-Labrèze C, Dumas de la Roque E, Hubiche T et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649–51.
10.1056/NEJMc0708819
CAS PubMed Web of Science® Google Scholar
10Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997; 13: 375–423.
CAS PubMed Google Scholar
11Bernstein D. Evaluation of the cardiovascular system. In: Nelson Textbook of Pediatrics, 16th edn ( RE Behrman, RM Kliegman, HB Jenson, eds). Beijing: Science Press, 2001; 1343–50.
Google Scholar
12Jephson CG, Manunza F, Syed S et al. Successful treatment of isolated subglottic haemangioma with propranolol alone. Int J Pediatr Otorhinolaryngol 2009; 73: 1821–3.
10.1016/j.ijporl.2009.08.020
PubMed Web of Science® Google Scholar
13Buckmiller LM. Propranolol treatment for infantile hemangiomas. Curr Opin Otolaryngol Head Neck Surg 2009; 17: 458–9.
10.1097/MOO.0b013e328332a4eb
PubMed Web of Science® Google Scholar
14Wahlgren CF. [Propranolol first choice in infantile hemangiomas. Large randomized trials are needed to determine the dosage and duration of treatment]. Läkartidningen 2013; 110: 938–9 (in Swedish).
PubMed Google Scholar
15Xiao Q, Li Q, Zhang B, Yu W. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. Pediatr Surg Int 2013; 29: 575–81.
10.1007/s00383-013-3283-y
PubMed Web of Science® Google Scholar
16Aletaha M, Salour H, Bagheri A et al. Oral propranolol for treatment of pediatric capillary hemangiomas. J Ophthalmic Vis Res 2012; 7: 130–3.
PubMed Google Scholar
17Love JN, Sikka N. Are 1–2 tablets dangerous? Beta-blocker exposure in toddlers. J Emerg Med 2004; 26: 309–14.
10.1016/j.jemermed.2003.11.015
PubMed Web of Science® Google Scholar
18Gan LQ, Ni SL, Tan Q, Wang H. A retrospective study of propranolol therapy in 109 infants with infantile hemangioma. Pediatr Dermatol 2013; 30: 270–2.
10.1111/pde.12046
CAS PubMed Web of Science® Google Scholar
19Hermans DJ, Bauland CG, Zweegers J et al. Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. Br J Dermatol 2013; 168: 837–43.
10.1111/bjd.12189
CAS PubMed Web of Science® Google Scholar
20Holland KE, Frieden IJ, Frommelt PC et al. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010; 146: 775–8.
10.1001/archdermatol.2010.158
CAS PubMed Web of Science® Google Scholar
21Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol 2011; 28: 169–71.
10.1111/j.1525-1470.2010.01224.x
PubMed Web of Science® Google Scholar
22Abbott J, Parulekar M, Shahidullah H et al. Diarrhea associated with propranolol treatment for hemangioma of infancy (HOI). Pediatr Dermatol 2010; 27: 558.
10.1111/j.1525-1470.2010.01221.x
CAS PubMed Web of Science® Google Scholar
23De Graaf M, Breur JM, Raphaël MF et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 2011; 65: 320–7.
10.1016/j.jaad.2010.06.048
CAS PubMed Web of Science® Google Scholar
24Siegfried EC, Keenan WJ, AI-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med 2008; 359: 2846–7.
10.1056/NEJMc086443
CAS PubMed Web of Science® Google Scholar
25Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 2011; 64: 292–9.
10.1016/j.bjps.2010.06.010
PubMed Web of Science® Google Scholar
26Kent AL, Kecskes Z, Shadbolt B, Falk MC. Blood pressure in the first year of life in healthy infants born at term. Pediatr Nephrol 2007; 22: 1743–9.
10.1007/s00467-007-0561-8
PubMed Web of Science® Google Scholar
27Ma X, Zhao T, Xiao Y. Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. Eur J Pediatr 2013; 172: 653–9.
10.1007/s00431-012-1928-9
CAS PubMed Web of Science® Google Scholar
28Torres-Pradilla M, Baselga E. Failure of intralesional propranolol in infantile hemangiomas. Pediatr Dermatol 2014; 31: 156–8.
10.1111/pde.12175
PubMed Web of Science® Google Scholar

Citing Literature

Volume172, Issue2

February 2015

Pages 444-449

Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment

Summary

Background

Objectives

Methods

Results

Conclusions

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment

Summary

Background

Objectives

Methods

Results

Conclusions

References

Citing Literature

References

Related

Information